Walgreens Boots Alliance, Inc. operates as a healthcare, pharmacy, and retail company in the United States, the United Kingdom, Germany, and internationally. It operates through three segments: U.S. Retail Pharmacy, International, and U.S. Healthcare. The U.S. Retail Pharmacy segment engages in operation of the retail drugstores, health and wellness services, specialty, and home delivery pharmacy services, which offers health and wellness, beauty, personal care and consumables, and general merchandise. The International segment offers sale of prescription drugs and health and wellness, beauty, personal care, and other consumer products outside the United States; and operates pharmacy-led health and beauty retail businesses under the Boots brand stores in the United Kingdom, the Republic of Ireland, and Thailand, as well as the Benavides brand in Mexico and the Ahumada brand in Chile. The U.S. Healthcare segment provides VillageMD, a national provider of value-based care with primary, multi-specialty, and urgent care providers serving patients in traditional clinic settings, in patients' homes and online appointments; Shields, a specialty pharmacy integrator and accelerator for hospitals; and CareCentrix, a participant in the post-acute and home care management sectors. Walgreens Boots Alliance, Inc. was founded in 1909 and is headquartered in Deerfield, Illinois.

Walgreens Boots Alliance, Inc.

Elevance Health (NYSE:ELV) is scheduled to announce its earnings on Thursday, July 17, 2025. For event-driven traders, examining historical stock performance around earnings releases can provide valuable insights and potentially enhance trading strategies.
Over the past five years, ELV has demonstrated positive one-day stock returns in 55% of instances following earnings reports. The median positive return on these days was 2.7%, with a maximum one-day positive return reaching 7.7%. Separately, cryptocurrencies have started to move again. See Will The Rally In XRP Price Continue?
Traders can approach earnings announcements with two main strategies:
Pre-Earnings Positioning: Based on the historical probabilities, one might consider establishing a position before the earnings report is released.
Post-Earnings Positioning: Alternatively, traders can wait for the earnings announcement and then analyze the relationship between immediate and medium-term returns to guide their subsequent trading decisions.
Analysts’ consensus estimates for Elevance Health’s upcoming report are earnings of $9.19 per share on revenue of $48.26 billion. This is in contrast to the year-ago quarter, where the company reported earnings of $10.12 per share on revenue of $43.22 billion.
From a fundamental standpoint, Elevance Health currently holds a market capitalization of $77 billion. Over the last twelve months, the company generated $183 billion in revenue and reported a net income of $5.9 billion.
That said, if you seek upside with lower volatility than individual stocks, the Trefis High Quality portfolio presents an alternative — having outperformed the S&P 500 and generated returns exceeding 91% since its inception. Also, see the potential for growth in Google Stock To $350?
See earnings reaction history of all stocks
Elevance Health’s Historical Odds Of Positive Post-Earnings Return
Some observations on one-day (1D) post-earnings returns:
There are 18 earnings data points recorded over the last five years, with 11 positive and 7 negative one-day (1D) returns observed. In summary, positive 1D returns were seen about 61% of the time.
Notably, this percentage increases to 73% if we consider data for the last 3 years instead of 5.
Median of the 11 positive returns = 2.7%, and median of the 7 negative returns = -5.3%
Additional data for observed 5-Day (5D), and 21-Day (21D) returns post earnings are summarized along with the statistics in the table below.
Correlation Between 1D, 5D, and 21D Historical Returns
A relatively less risky strategy (though not useful if the correlation is low) is to understand the correlation between short-term and medium-term returns post earnings, find a pair that has the highest correlation, and execute the appropriate trade. For example, if 1D and 5D show the highest correlation, a trader can position themselves “long” for the next 5 days if 1D post-earnings return is positive. Here is some correlation data based on 5-year and 3-year (more recent) history. Note that the correlation 1D_5D refers to the correlation between 1D post-earnings returns and subsequent 5D returns.
Learn more about Trefis RV strategy that has outperformed its all-cap stocks benchmark (combination of all 3, the S&P 500, S&P mid-cap, and Russell 2000), to produce strong returns for investors. Separately, if you want upside with a smoother ride than an individual stock like Elevance Health, consider the High Quality portfolio, which has outperformed the S&P, and clocked >91% returns since inception.
Invest with Trefis Market-Beating Portfolios
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

How Will Elevance Health Stock React To Its Upcoming Earnings?

(RTTNews) - Walgreens Boots Alliance (WBA), Friday confirmed that its shareholders overwhelmingly approved the planned acquisition by Sycamore Partners at a Special Meeting, with approximately 96 percent of all votes and 95 percent of unaffiliated shareholder votes in favor of the merger.
Under the deal, WBA investors will receive $11.45 in cash per share plus one non-transferable right to claim up to an additional $3.00 per share from future proceeds on WBA's stakes in VillageMD's Village Medical, Summit Health, and CityMD businesses.
The transaction remains on track to close in Q3 or Q4 2025.
WBA is currently trading at $11.52, down $0.04 or 0.30 percent on the Nasdaq.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Walgreens Shareholders Greenlight $11.45 Bln Sycamore Buyout

Walgreens Boots Alliance (WBA) reported $38.99 billion in revenue for the quarter ended May 2025, representing a year-over-year increase of 7.3%. EPS of $0.38 for the same period compares to $0.63 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $36.61 billion, representing a surprise of +6.49%. The company delivered an EPS surprise of +11.76%, with the consensus EPS estimate being $0.34.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Walgreens performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Revenues- U.S. Retail Pharmacy: $30.72 billion compared to the $28.76 billion average estimate based on four analysts. The reported number represents a change of +7.8% year over year.
Revenues- U.S. Healthcare: $2.10 billion versus $2.17 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -1.1% change.
Revenues- International: $6.17 billion versus the four-analyst average estimate of $5.74 billion. The reported number represents a year-over-year change of +7.8%.
Adjusted operating income (loss)- U.S. Retail Pharmacy: $350 million versus the two-analyst average estimate of $113.67 million.
Adjusted operating income (loss)- Corporate and Other: -$60 million versus the two-analyst average estimate of -$52.50 million.
Adjusted operating income (loss)- U.S. Healthcare: $54 million versus the two-analyst average estimate of $72.85 million.
Adjusted operating income (loss)- International: $214 million versus $196.39 million estimated by two analysts on average.
View all Key Company Metrics for Walgreens here>>>
Shares of Walgreens have returned +1.1% over the past month versus the Zacks S&P 500 composite's +5.1% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Compared to Estimates, Walgreens (WBA) Q3 Earnings: A Look at Key Metrics

Walgreens Boots Alliance, Inc. WBA delivered adjusted earnings per share (EPS) of 38 cents in the third quarter of fiscal 2025, down 39.7% from the year-ago quarter’s figure (down 39.6% at the constant exchange rate or CER). However, the figure topped the Zacks Consensus Estimate by 11.76%.
GAAP loss per share for the third quarter was 20 cents compared to the year-ago quarter’s EPS of 40 cents.
WBA’s Q3 Sales
Walgreens Boots recorded total sales of $38.99 billion in the fiscal third quarter, up 7.2% year over year and 6.9% at CER. The top line also surpassed the Zacks Consensus Estimate by 6.5%.
Following the announcement, Walgreens shares rose 0.9% in the pre-market session today.
Segmental Insights of WBA’s Q3 Revenues
The company currently operates its business through three reportable segments: U.S. Retail Pharmacy, International and U.S. Healthcare.
U.S. Retail Pharmacy
The segment’s sales increased 7.8% year over year to $30.7 billion in the fiscal third quarter. Comparable sales jumped 10.3% from the year-ago quarter’s levels.
Pharmacy sales were up 11.8% from the year-ago quarter’s figures, and comparable pharmacy sales increased 14.6%, each benefiting from higher branded drug inflation and mix impacts.
Retail sales fell 5.3%, and comparable retail sales were down 2.4% year over year due to weaker sales in grocery and household, health and wellness, and beauty.
International
Revenues in the International division rose 7.8% on a year-over-year basis and increased 5.9% at CER to $6.2 billion in the fiscal third quarter.
In Germany, wholesale business sales increased 6.8% in the fiscal third quarter.
Walgreens Boots Alliance, Inc. Price, Consensus and EPS Surprise
Boots UK sales rose 5% year over year. Its comparable retail sales advanced 6%. Further, Boots UK comparable pharmacy sales increased 5.4% year over year at CER.
U.S. Healthcare
U.S. Healthcare reported fiscal third-quarter revenues of $2.1 billion. Within the segment, VillageMD sales decreased 6.5% year over year, while CareCentrix and Shields sales increased 11.6% and 24.8%, respectively.
WBA’s Q3 Margin Performance
The gross profit in the reported quarter increased 075% year over year to $6.51 billion despite an 8.7% rise in the cost of sales. The gross margin contracted 108 basis points to 16.7%.
Selling, general and administrative (SG&A) expenses increased 1.6% year over year to $6.49 billion.
The company reported an adjusted operating profit of $13 million for the quarter compared with the year-ago period’s profit of $66 million. (See the Zacks Earnings Calendar to stay ahead of market-making news.)
WBA’s Liquidity & Cash Flow Position
Walgreens Boots exited the third quarter of fiscal 2025 with cash and cash equivalents of $766 million compared with $702 million at the second quarter-end.
The total debt was $7.37 billion compared with $8.01 billion at the end of the fiscal second quarter.
The cumulative cash used by operating activities at the end of the third quarter of fiscal 2025 was $245 million compared with the year-ago period’s outflow of $314 million.
Walgreens Withdraws 2025 Guidance Amid Pending Deal
On March 6, 2025, WBA signed a definitive agreement to be acquired by entities affiliated with Sycamore Partners. The merger is expected to close in the third or fourth quarter of the calendar year 2025, pending shareholder and regulatory approvals and other conditions to closing.
Following the close of the transaction, WBA will become a private company, and its common stock will be delisted from the Nasdaq stock market. In light of the pending transaction, the company has withdrawn issuing fiscal 2025 guidance. Furthermore, Walgreens' previously issued guidance for the full year is no longer in effect.
Our Take on WBA Stock
Walgreens Boots ended the third quarter of fiscal 2025 with better-than-expected earnings and revenues. The results reflected continued improvement in the U.S. Healthcare segment and gains from the cost savings initiatives. At the same time, U.S. front-end sales remained soft. Walgreens Boots’ bottom line was down on a year-over-year basis. A contraction of the gross margin in the quarter is discouraging. WBA management remains committed to its turnaround plan, which will require time and a disciplined, balanced approach to align future cash needs with necessary investments in a changing pharmacy and retail environment.
WBA’s Zacks Rank & Other Key Picks
Walgreens Boots currently carries a Zacks Rank #2 (Buy). Some other top-ranked stocks from the broader medical space are Veeva Systems VEEV, Intuitive Surgical ISRG and Integer Holdings ITGR.
Veeva Systems, currently sporting a Zacks Rank #1 (Strong Buy), reported first-quarter fiscal 2026 adjusted EPS of $1.97, which surpassed the Zacks Consensus Estimate by 13.2%. Revenues of $759 million beat the consensus mark by 4.3%. You can see the complete list of today’s Zacks #1 Rank stocks here.
VEEV has an estimated long-term earnings growth rate of 23.3% compared to the industry’s 19.1% growth. The company surpassed earnings estimates in each of the trailing four quarters, the average surprise being 10%.
Intuitive Surgical, carrying a Zacks Rank #2 at present, posted first-quarter 2025 adjusted EPS of $1.81, exceeding the Zacks Consensus Estimate by 5.9%. Revenues of $2.25 billion surpassed the Zacks Consensus Estimate by 3.3%.
ISRG has an estimated long-term earnings growth rate of 15.1% compared to the industry’s 14.4% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 14.6%.
Integer Holdings, carrying a Zacks Rank #2, reported a first-quarter 2025 adjusted EPS of $1.14, which beat the Zacks Consensus Estimate by 1.8%. Revenues of $414.8 million topped the Zacks Consensus Estimate by 0.4%.
ITGR has a long-term earnings growth rate of 18.4% compared to the industry’s 14.4% growth. The company’s earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 2.8%.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Walgreens Q3 Earnings Top Estimates, Stock Up, Gross Margin Declines

Walgreens Boots Alliance (WBA) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of $0.34 per share. This compares to earnings of $0.63 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +11.76%. A quarter ago, it was expected that this largest U.S. drugstore chain would post earnings of $0.53 per share when it actually produced earnings of $0.63, delivering a surprise of +18.87%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Walgreens, which belongs to the Zacks Retail - Pharmacies and Drug Stores industry, posted revenues of $38.99 billion for the quarter ended May 2025, surpassing the Zacks Consensus Estimate by 6.49%. This compares to year-ago revenues of $36.35 billion. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Walgreens shares have added about 21.2% since the beginning of the year versus the S&P 500's gain of 3.6%.
What's Next for Walgreens?
While Walgreens has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Walgreens was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.25 on $36.98 billion in revenues for the coming quarter and $1.69 on $151.46 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Retail - Pharmacies and Drug Stores is currently in the top 2% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the broader Zacks Retail-Wholesale sector, Genuine Parts (GPC), has yet to report results for the quarter ended June 2025.
This auto and industrial parts distributor is expected to post quarterly earnings of $2.08 per share in its upcoming report, which represents a year-over-year change of -14.8%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Genuine Parts' revenues are expected to be $6.11 billion, up 2.6% from the year-ago quarter.
Should You Invest in Walgreens Boots Alliance, Inc. (WBA)?
Before you invest in Walgreens Boots Alliance, Inc. (WBA), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks to buy.
Zacks Investment Research has been committed to providing investors with tools and independent research since 1978. For more than a quarter century, the Zacks Rank stock-rating system has more than doubled the S&P 500 with an average gain of +24.08% per year. (These returns cover a period from January 1, 1988 through May 6, 2024.)
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Walgreens Boots Alliance (WBA) Q3 Earnings and Revenues Beat Estimates

(RTTNews) - Walgreens Boots Alliance Inc. (WBA), which is in deal to be taken private by Sycamore Partners, reported Thursday a net loss in its third quarter, compared to prior year's profit, despite higher net sales.
Due to the pending up to $23.7 billion deal, WBA has withdrawn its previously issued annual guidance, and it will not host a conference call.
Net loss attributable to the company in the third quarter was $175 million, compared to net earnings of $344 million in the year-ago quarter. Loss per share was $0.20, compared to earnings per share of $0.40 last year.
Adjusted net earnings were $334 million, compared to $545 million a year ago. Adjusted earnings per share were $0.38, compared to $0.63 in the prior year.
The Wall Street analysts on average expected the company to report earnings of $0.34 per share. Analysts' estimates typically exclude special items.
The third-quarter sales increased 7.2 percent to $39.0 billion from last year's $36.35 billion. The Street expected sales of $36.72 billion for the quarter.
The increase was 6.9 percent on a constant currency basis, reflecting sales growth in the U.S. Retail Pharmacy and International segments.
Chief Executive Officer Tim Wentworth said, "Third quarter results reflect continued improvement in our U.S. Healthcare segment and benefits from our cost savings initiatives, while we continued to see weakness in our U.S. front-end sales. We remain focused on our turnaround plan, which will require time, disciplined focus and a balanced approach to manage future cash needs with investments necessary to navigate an evolving pharmacy and retail environment."
The merger is currently expected to close in the third or fourth quarter of calendar year 2025, pending shareholder and regulatory approvals and other conditions to closing.
Following the deal closure, WBA common stock will no longer be listed on the Nasdaq Stock Market, and WBA will become a private company.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Walgreens Slips To Loss In Q3; Adj. Earnings, Sales Beat Market

We just received data on a new analyst forecast for $WBA. Morgan Stanley gave a rating of 'Underweight' for $WBA.
$WBA Analyst Ratings
Wall Street analysts have issued reports on $WBA in the last several months. We have seen 0 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
Morgan Stanley issued a "Underweight" rating on 06/26/2025
To track analyst ratings and price targets for $WBA, check out Quiver Quantitative's $WBA forecast page.
$WBA Congressional Stock Trading
Members of Congress have traded $WBA stock 3 times in the past 6 months. Of those trades, 1 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $WBA stock by members of Congress over the last 6 months:
REPRESENTATIVE JULIE JOHNSON has traded it 2 times. They made 1 purchase worth up to $15,000 on 01/15 and 1 sale worth up to $15,000 on 02/12.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$WBA Insider Trading Activity
$WBA insiders have traded $WBA stock on the open market 2 times in the past 6 months. Of those trades, 1 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $WBA stock by insiders over the last 6 months:
STEFANO PESSINA (Executive Chairman of Board) has made 1 purchase buying 832,258 shares for an estimated $9,163,160 and 1 sale selling 832,258 shares for an estimated $9,163,160.
$WBA Hedge Fund Activity
We have seen 364 institutional investors add shares of $WBA stock to their portfolio, and 587 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
BLACKROCK, INC. removed 12,071,483 shares (-16.6%) from their portfolio in Q1 2025, for an estimated $134,838,465
FMR LLC added 9,562,516 shares (+367.4%) to their portfolio in Q1 2025, for an estimated $106,813,303
INVESCO LTD. removed 9,355,670 shares (-28.7%) from their portfolio in Q1 2025, for an estimated $104,502,833
CANDLESTICK CAPITAL MANAGEMENT LP added 7,723,212 shares (+inf%) to their portfolio in Q1 2025, for an estimated $86,268,278
STATE STREET CORP removed 7,477,937 shares (-17.4%) from their portfolio in Q1 2025, for an estimated $83,528,556
TWO SIGMA ADVISERS, LP removed 6,895,400 shares (-89.1%) from their portfolio in Q1 2025, for an estimated $77,021,618
GLAZER CAPITAL, LLC added 5,071,180 shares (+inf%) to their portfolio in Q1 2025, for an estimated $56,645,080
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

New Analyst Forecast: $WBA Given 'Underweight' Rating

The following companies are expected to report earnings prior to market open on 06/26/2025. Visit our Earnings Calendar for a full list of expected earnings releases.
McCormick & Company, Incorporated (MKC)is reporting for the quarter ending May 31, 2025. The food company's consensus earnings per share forecast from the 6 analysts that follow the stock is $0.65. This value represents a 5.80% decrease compared to the same quarter last year. MKC missed the consensus earnings per share in the 1st calendar quarter of 2025 by -6.25%. Zacks Investment Research reports that the 2025 Price to Earnings ratio for MKC is 24.74 vs. an industry ratio of 16.60, implying that they will have a higher earnings growth than their competitors in the same industry.
Walgreens Boots Alliance, Inc. (WBA)is reporting for the quarter ending May 31, 2025. The drug store company's consensus earnings per share forecast from the 5 analysts that follow the stock is $0.34. This value represents a 46.03% decrease compared to the same quarter last year. WBA missed the consensus earnings per share in the 2nd calendar quarter of 2024 by -5.97%. Zacks Investment Research reports that the 2025 Price to Earnings ratio for WBA is 6.84 vs. an industry ratio of 5.60, implying that they will have a higher earnings growth than their competitors in the same industry.
Acuity Inc. (AYI)is reporting for the quarter ending May 31, 2025. The technology services company's consensus earnings per share forecast from the 5 analysts that follow the stock is $4.11. This value represents a 6.48% increase compared to the same quarter last year. In the past year AYI has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 2.68%. Zacks Investment Research reports that the 2025 Price to Earnings ratio for AYI is 17.99 vs. an industry ratio of 34.40.
Lindsay Corporation (LNN)is reporting for the quarter ending May 31, 2025. The farm machinery company's consensus earnings per share forecast from the 2 analysts that follow the stock is $1.36. This value represents a 3.55% decrease compared to the same quarter last year. In the past year LNN has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 29.1%. Zacks Investment Research reports that the 2025 Price to Earnings ratio for LNN is 21.04 vs. an industry ratio of 46.30.
HIVE Digital Technologies Ltd (HIVE)is reporting for the quarter ending March 31, 2025. The financial services company's consensus earnings per share forecast from the 4 analysts that follow the stock is $-0.11. This value represents a 266.67% decrease compared to the same quarter last year. In the past year HIVE has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2025 Price to Earnings ratio for HIVE is -5.61 vs. an industry ratio of 23.90.
Orion Energy Systems, Inc. (OESX)is reporting for the quarter ending March 31, 2025. The building company's consensus earnings per share forecast from the 1 analyst that follows the stock is $-0.06. This value represents a 500.00% decrease compared to the same quarter last year. OESX missed the consensus earnings per share in the 3rd calendar quarter of 2024 by -22.22%. Zacks Investment Research reports that the 2025 Price to Earnings ratio for OESX is -1.79 vs. an industry ratio of 11.10.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Pre-Market Earnings Report for June 26, 2025 : MKC, WBA, AYI, LNN, HIVE, OESX

The upcoming report from Walgreens Boots Alliance (WBA) is expected to reveal quarterly earnings of $0.34 per share, indicating a decline of 46% compared to the year-ago period. Analysts forecast revenues of $36.66 billion, representing an increase of 0.9% year over year.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
In light of this perspective, let's dive into the average estimates of certain Walgreens metrics that are commonly tracked and forecasted by Wall Street analysts.
The average prediction of analysts places 'Revenues- U.S. Retail Pharmacy' at $28.76 billion. The estimate indicates a year-over-year change of +0.9%.
Analysts predict that the 'Revenues- U.S. Healthcare' will reach $2.17 billion. The estimate suggests a change of +2.3% year over year.
According to the collective judgment of analysts, 'Revenues- International' should come in at $5.74 billion. The estimate suggests a change of +0.2% year over year.
Analysts forecast 'Adjusted operating income (loss)- U.S. Retail Pharmacy' to reach $113.67 million. The estimate is in contrast to the year-ago figure of $501 million.
Analysts expect 'Adjusted operating income (loss)- International' to come in at $196.39 million. The estimate is in contrast to the year-ago figure of $175 million.
View all Key Company Metrics for Walgreens here>>>
Shares of Walgreens have experienced a change of +1.3% in the past month compared to the +0.5% move of the Zacks S&P 500 composite. With a Zacks Rank #2 (Buy), WBA is expected to outperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Unveiling Walgreens (WBA) Q3 Outlook: Wall Street Estimates for Key Metrics

Darden Restaurants (DRI) came out with quarterly earnings of $2.98 per share, beating the Zacks Consensus Estimate of $2.96 per share. This compares to earnings of $2.65 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 0.68%. A quarter ago, it was expected that this owner of Olive Garden and other chain restaurants would post earnings of $2.81 per share when it actually produced earnings of $2.80, delivering a surprise of -0.36%.
Over the last four quarters, the company has surpassed consensus EPS estimates just once.
Darden Restaurants, which belongs to the Zacks Retail - Restaurants industry, posted revenues of $3.27 billion for the quarter ended May 2025, surpassing the Zacks Consensus Estimate by 0.18%. This compares to year-ago revenues of $2.96 billion. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Darden Restaurants shares have added about 19.3% since the beginning of the year versus the S&P 500's gain of 1.7%.
What's Next for Darden Restaurants?
While Darden Restaurants has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Darden Restaurants: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $1.93 on $3.04 billion in revenues for the coming quarter and $10.70 on $13.16 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Retail - Restaurants is currently in the bottom 36% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the broader Zacks Retail-Wholesale sector, Walgreens Boots Alliance (WBA), is yet to report results for the quarter ended May 2025. The results are expected to be released on June 26.
This largest U.S. drugstore chain is expected to post quarterly earnings of $0.34 per share in its upcoming report, which represents a year-over-year change of -46%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Walgreens Boots Alliance's revenues are expected to be $36.66 billion, up 0.9% from the year-ago quarter.
Should You Invest in Darden Restaurants, Inc. (DRI)?
Before you invest in Darden Restaurants, Inc. (DRI), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks to buy.
Zacks Investment Research has been committed to providing investors with tools and independent research since 1978. For more than a quarter century, the Zacks Rank stock-rating system has more than doubled the S&P 500 with an average gain of +24.08% per year. (These returns cover a period from January 1, 1988 through May 6, 2024.)
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Darden Restaurants, Inc. (DRI) : Free Stock Analysis Report
Walgreens Boots Alliance, Inc. (WBA) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Walgreens Boots Alliance, Inc.

Fundamental analysis

Ratios

Valuation

Debts

Efficiency

Other ratios

Revenue

Financials

Growth

Assets

Debts